牛唐2021-03-31 09:44
$灿菲特生物制药(CANF)$ 的药物Piclidenoson和Namodenoson在现有的六份分销协议中,剩余的潜在里程碑付款高达约1.3亿美元,外加两位数的净销售额分成。$新泰医药(MDGL)$ $泰格医药(SZ300347)$查看全文
$灿菲特生物制药(CANF)$ D Notice of Exempt Offering of Securities, item 06b Accession Number: 0001213900-21-045051 Act: 33 Size: 12 KB 网页链接
$灿菲特生物制药(CANF)$ POS AM Post-Effective amendments for registration statement Accession Number: 0001213900-21-045053 Act: 33 Size: 570 KB 网页链接
$灿菲特生物制药(CANF)$ F-1 Registration statement for certain foreign private issuers Accession Number: 0001213900-21-045052 Act: 33 Size: 601 KB 网页链接
$灿菲特生物制药(CANF)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001213900-21-044894 Act: 34 Size: 2 MB 网页链接
$灿菲特生物制药(CANF)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001213900-21-042704 Act: 34 Size: 646 KB 网页链接
$灿菲特生物制药(CANF)$ 424B5 Prospectus [Rule 424(b)(5)] Accession Number: 0001213900-21-042522 Act: 33 Size: 644 KB 网页链接
$灿菲特生物制药(CANF)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001213900-21-041810 Act: 34 Size: 25 KB 网页链接
$灿菲特生物制药(CANF)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001213900-21-040436 Act: 34 Size: 21 KB 网页链接
$灿菲特生物制药(CANF)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001213900-21-039301 Act: 34 Size: 11 KB 网页链接
$灿菲特生物制药(CANF)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001213900-21-036050 Act: 34 Size: 24 KB 网页链接